Forte Biosciences (FBRX) Free Cash Flow (2016 - 2026)
Forte Biosciences (FBRX) reported Free Cash Flow of -$18.8 million for Q1 2026, down 80.57% year-over-year from -$96.8 million in Q1 2025, and down 14.1% quarter-over-quarter from -$16.5 million in Q4 2025.
Forte Biosciences (FBRX) Free Cash Flow (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Free Cash Flow data on file, last reported at -$18.8 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$18.8 million, down 80.57% year-over-year; the trailing twelve-month figure through Mar 2026 was -$59.4 million (down 72.07% YoY), and the FY2025 annual result was -$51.0 million, down 65.73% from the prior year.
- Free Cash Flow fell to -$18.8 million in Q1 2026 per FBRX's latest filing, from -$16.5 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$1.4 million in Q2 2022 and troughed at -$18.8 million in Q1 2026.
- A 5-year average of -$8.1 million and a median of -$8.1 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow surged 65.03% in 2022, then slumped 366.91% in 2023.
- A 5-year view of Free Cash Flow shows it stood at -$2.9 million in 2022, then plunged by 212.03% to -$9.0 million in 2023, then retreated by 11.22% to -$10.0 million in 2024, then slumped by 64.18% to -$16.5 million in 2025, then declined by 14.1% to -$18.8 million in 2026.
- Business Quant data shows FBRX's Free Cash Flow at -$18.8 million in Q1 2026, -$16.5 million in Q4 2025, and -$14.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | -18.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.81 Mn |
| Mar 31, 2026 | -18.81 Mn |
| Dec 31, 2025 | -16.48 Mn |
| Dec 31, 2025 | -16.48 Mn |
| Sep 30, 2025 | -14.06 Mn |
| Sep 30, 2025 | -14.06 Mn |
| Jun 30, 2025 | -10.06 Mn |
| Jun 30, 2025 | -10.06 Mn |
| Mar 31, 2025 | -10.42 Mn |
| Mar 31, 2025 | -10.42 Mn |
| Dec 31, 2024 | -10.04 Mn |
| Dec 31, 2024 | -10.04 Mn |
| Sep 30, 2024 | -8.13 Mn |
| Sep 30, 2024 | -8.13 Mn |
| Jun 30, 2024 | -5.94 Mn |
| Jun 30, 2024 | -5.94 Mn |
| Mar 31, 2024 | -6.67 Mn |
| Mar 31, 2024 | -6.67 Mn |
| Dec 31, 2023 | -9.03 Mn |
| Dec 31, 2023 | -9.03 Mn |